165 related articles for article (PubMed ID: 30901703)
1. A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions.
Diebold M; Müller S; Derfuss T; Décard BF
Mult Scler Relat Disord; 2019 Jun; 31():38-40. PubMed ID: 30901703
[TBL] [Abstract][Full Text] [Related]
2. Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis.
Shima A; Hamaguchi T; Tada Y; Yamada M
Intern Med; 2020 Jan; 59(1):121-124. PubMed ID: 31462595
[TBL] [Abstract][Full Text] [Related]
3. Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Parfenov V; Du Pasquier R; Schluep M
Neurologist; 2015 Jun; 19(6):155-7. PubMed ID: 26075469
[TBL] [Abstract][Full Text] [Related]
4. The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis.
Zhong M; van der Walt A; Campagna MP; Stankovich J; Butzkueven H; Jokubaitis V
Neurotherapeutics; 2020 Oct; 17(4):1768-1784. PubMed ID: 33058021
[TBL] [Abstract][Full Text] [Related]
5. Ocrelizumab (Ocrevus) for MS.
Med Lett Drugs Ther; 2017 Jun; 59(1523):98-101. PubMed ID: 28609424
[No Abstract] [Full Text] [Related]
6. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
[TBL] [Abstract][Full Text] [Related]
7. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for relapsing-remitting multiple sclerosis.
He D; Zhou H; Han W; Zhang S
Cochrane Database Syst Rev; 2011 Dec; (12):CD009130. PubMed ID: 22161445
[TBL] [Abstract][Full Text] [Related]
9. Psoriasis during interferon beta treatment for multiple sclerosis.
La Mantia L; Capsoni F
Neurol Sci; 2010 Jun; 31(3):337-9. PubMed ID: 19924503
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
11. Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmas.
Pfeuffer S
Mult Scler; 2024 Jun; 30(7):897-898. PubMed ID: 38385204
[No Abstract] [Full Text] [Related]
12. Pancolitis a novel early complication of Alemtuzumab for MS treatment.
Vijiaratnam N; Rath L; Xu SS; Skibina O
Mult Scler Relat Disord; 2016 May; 7():83-4. PubMed ID: 27237765
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in relapsing-remitting multiple sclerosis.
Chaudhuri A; Behan PO
N Engl J Med; 2008 Jun; 358(24):2646; author reply 2646-7. PubMed ID: 18557178
[No Abstract] [Full Text] [Related]
14. Update on disease-modifying treatments for multiple sclerosis.
Carrithers MD
Clin Ther; 2014 Dec; 36(12):1938-1945. PubMed ID: 25218310
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.
Hu Y; Nie H; Yu HH; Qin C; Wu LJ; Tang ZP; Tian DS
Autoimmun Rev; 2019 May; 18(5):542-548. PubMed ID: 30844555
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis during natalizumab treatment for multiple sclerosis.
Millán-Pascual J; Turpín-Fenoll L; Del Saz-Saucedo P; Rueda-Medina I; Navarro-Muñoz S
J Neurol; 2012 Dec; 259(12):2758-60. PubMed ID: 23096069
[TBL] [Abstract][Full Text] [Related]
17. Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients.
Woo MS; Steins D; Häußler V; Kohsar M; Haag F; Elias-Hamp B; Heesen C; Lütgehetmann M; Schulze Zur Wiesch J; Friese MA
J Neurol; 2021 Jan; 268(1):5-7. PubMed ID: 32654064
[No Abstract] [Full Text] [Related]
18. Rituximab in relapsing-remitting multiple sclerosis.
De Palma R; Sementa A
N Engl J Med; 2008 Jun; 358(24):2645-6; author reply 2646-7. PubMed ID: 18550883
[No Abstract] [Full Text] [Related]
19. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.
Cross AH; Stark JL; Lauber J; Ramsbottom MJ; Lyons JA
J Neuroimmunol; 2006 Nov; 180(1-2):63-70. PubMed ID: 16904756
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis.
Di Tullio F; Odorici G; Lasagni C; Capobianco M; Conti A; Mandel VD
Dermatol Ther; 2020 Nov; 33(6):e13943. PubMed ID: 32614114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
